Scholarlink

Purpose of Review <p>Physiologically based pharmacokinetic (PBPK) modeling offers an effective means to explore how disease-related pathophysiological variations affect drug pharmacokinetics (PK). This systematic review aims to evaluate and synthesize existing studies on PBPK models of drugs used in the treatment of chronic pulmonary diseases (CPDs).</p> Recent Findings <p>A total of twenty studies were identified across five databases, with the majority (55%) focusing on tuberculosis (TB). Genetic polymorphisms were the most frequently modeled variable in 35% of studies. All the studies reported good agreement between predicted PKs and observed clinical data. However, one study underpredicted results for three out of their four included drugs.</p> Summary <p> Significant progress has been made in PBPK modeling within pulmonary medicine, particularly in the research of TB drugs. However, there are inconsistencies in validation practices and the lack of a standardized tool for quality assessment in simulation studies, which remain as limitations in the field.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A Systematic Review of Physiologically Based Pharmacokinetic Models for Drugs Used in Chronic Pulmonary Diseases

  • 期刊论文

  • 发表日期：

    2026年6月16日

查看全文
  • Safeer Khan,
  • Muhammad Nasir Kalam,
  • Muhammad Aamir,
  • Saimon Shahzad,
  • Nadia Kausar,
  • Hafiz Majid Rasheed

摘要

Purpose of Review

Physiologically based pharmacokinetic (PBPK) modeling offers an effective means to explore how disease-related pathophysiological variations affect drug pharmacokinetics (PK). This systematic review aims to evaluate and synthesize existing studies on PBPK models of drugs used in the treatment of chronic pulmonary diseases (CPDs).

Recent Findings

A total of twenty studies were identified across five databases, with the majority (55%) focusing on tuberculosis (TB). Genetic polymorphisms were the most frequently modeled variable in 35% of studies. All the studies reported good agreement between predicted PKs and observed clinical data. However, one study underpredicted results for three out of their four included drugs.

Summary

Significant progress has been made in PBPK modeling within pulmonary medicine, particularly in the research of TB drugs. However, there are inconsistencies in validation practices and the lack of a standardized tool for quality assessment in simulation studies, which remain as limitations in the field.